Aptahem receives Intention to Grant from the European Patent Office for the protection of patent family 2
Aptahem AB (publ) announces today that the company has received information that the European Patent Office (EPO) has issued an Intention to Grant of the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The application covers the therapeutic protection of the company’s aptamer Apta-1 which is being developed as treatment for disease syndroms caused by inflammation, coagulation and/or organ failure.This application is part of the patent family 2 with Aptahem’s CSO Dr Luiza Jedlina as the inventor.